Dengue

• EMA withdrawal · 2025-12-04
  EMA Withdrawn: Dengvaxia (chimeric yellow fever dengue virus serotype 1 (live, attenuated);chimeric yellow fever dengue virus serotype 2 (live, attenuated);chimeric yellow fever dengue virus serotype 3 (live, attenuated);chimeric yellow fever dengue virus serotype 4 (live, attenuated)) — Sanofi Winthrop Industrie

  The EMA has withdrawn Dengvaxia from use in the European Union.

• CLINICAL_TRIALS withdrawal · 2025-01-10
  Clinical Trial Update: A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants [Phase 2]

  Phase 2 trial evaluating Janssen's dengue vaccine candidate JNJ-64281802 against dengue serotype 1 in a human challenge model has been withd…

• CLINICAL_TRIALS withdrawal · 2017-04-12
  Clinical Trial Update: TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant [Phase 1]

  A Phase 1 dengue vaccine trial evaluating a TDENV PIV and LAV prime-boost strategy with AS03B adjuvant has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2015-06-11
  Clinical Trial Update: Ability of Bedside Ultrasound to Predict Progression of Severity of Disease in Dengue Fever

  A clinical trial evaluating bedside ultrasound to predict progression of severity in dengue fever has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2015-04-03
  Clinical Trial Update: Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection

  The clinical trial NCT00629356 investigating immunoregulation and interactions with viral hepatitis in patients with dengue infection has be…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.